PARIS—Sanofi has named David Meeker as Chief Executive Officer of Genzyme, a Sanofi company, effective November 1.
Meeker will report to Christopher A. Viehbacher, CEO of Sanofi, and will join the Group Management Committee. Christopher A. Viehbacher will retain the position of Chairman, Genzyme.
“After working closely with David over the past six months, I am confident that he is the best person to lead Genzyme,” said Viehbacher. “David’s commitment to employees, physicians and patients has been a key success factor in the successful integration of Genzyme as part of the Sanofi Group. His combination of medical and business experience will be essential to move Genzyme’s broad portfolio of products forward and deliver much-needed therapies to patients.”
Under David Meeker’s leadership, Genzyme will incorporate the Rare Disease business and the Multiple Sclerosis franchise. Previous Genzyme divisions—Renal, Biosurgery and Oncology—have been integrated within the existing Sanofi portfolio.
David joined Genzyme in 1994 as Medical Director to work on the Cystic Fibrosis Gene Therapy program. Over the years he has held key positions of increasing responsibility as he led the development of treatments in the current rare disease portfolio. As President of the Global Rare Disease Business, he oversaw the global launches of Aldurazyme, Fabrazyme and Myozyme. In 2009, he was promoted to Chief Operating Officer of Genzyme and has played an important role in the integration since April of this year. David received his MD from the University of Vermont Medical School, and completed the Advanced Management Program at Harvard Business School in 2000.